Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.53 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.53 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8161941 | 0.82 | MGLL (0.61) | GRM5GRM3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3001297 | 0.82 | GRM5 (0.60) | GRM5GRM3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL30967272 | 0.82 | HSD11B1 (0.71) | GRM5L3MBTL1ALDH1A1HSD11B1MGLL | |
| SCHEMBL11007666 | 0.82 | MGLL (0.71) | GRM5ALDH1A1HPGDMAPTHSD11B1 | |
| SCHEMBL5880849 | 0.82 | HPGD (0.68) | GRM5GRM3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL12074789 | 0.82 | KMT2A (0.71) | GRM5GRM3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL3001302 | 0.82 | MGLL (0.61) | GRM5GRM3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL4003986 | 0.81 | GRM5 (0.73) | GRM5L3MBTL3L3MBTL1NAMPTALDH1A1 | |
| SCHEMBL95807 | 0.81 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2538732 | 0.81 | HPGD (0.76) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| CN-102964239-B | metal-beta-lactamase inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| CN-101267815-B | metallo-beta-lactamase inhibitors | MEIJI SEIKA PHARMA CO LTD | 2013-11-06 | — | — | CN | disclosed |
| CN-102964239-A | Metallo-beta-lactamase inhibitor | MEIJI SEIKA KAISHA | 2013-03-13 | — | — | CN | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| CN-101267815-A | metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | GRM5 1865/4885GRM3 3672/4885L3MBTL3 3019/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | GRM5 1865/4885GRM3 3672/4885L3MBTL3 3019/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | GRM5 2031/4885GRM3 3776/4885L3MBTL3 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.